



US009636330B2

(12) **United States Patent**  
**Ohata et al.**

(10) **Patent No.:** **US 9,636,330 B2**

(45) **Date of Patent:** **\*May 2, 2017**

(54) **TETRAHYDROCARBOLINE DERIVATIVE**

(71) Applicant: **ONO PHARMACEUTICAL CO., LTD.**, Osaka (JP)

(72) Inventors: **Akira Ohata**, Osaka (JP); **Shingo Nakatani**, Osaka (JP); **Tetsuya Sugiyama**, Ibaraki (JP); **Takashi Morimoto**, Osaka (JP)

(73) Assignee: **ONO PHARMACEUTICAL CO., LTD.**, Osaka-shi (JP)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/630,708**

(22) Filed: **Feb. 25, 2015**

(65) **Prior Publication Data**

US 2015/0231118 A1 Aug. 20, 2015

**Related U.S. Application Data**

(62) Division of application No. 13/807,947, filed as application No. PCT/JP2011/065312 on Jul. 5, 2011, now Pat. No. 9,006,246.

(30) **Foreign Application Priority Data**

Jul. 6, 2010 (JP) ..... 2010-154280  
Mar. 18, 2011 (JP) ..... 2011-060765

(51) **Int. Cl.**

**A61K 31/437** (2006.01)  
**A61K 31/4375** (2006.01)  
**A61K 31/496** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 31/437** (2013.01); **A61K 31/4375** (2013.01); **A61K 31/496** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2002/0010189 A1 1/2002 Sui et al.  
2004/0116458 A1 6/2004 Sawyer et al.  
(Continued)

**FOREIGN PATENT DOCUMENTS**

EA 010546 B1 10/2008  
JP 2003533453 11/2003  
(Continued)

**OTHER PUBLICATIONS**

Cecil's Textbook of Medicine, pp. 1060-1074, 2000.\*  
(Continued)

*Primary Examiner* — Anna Pagonakis

(74) *Attorney, Agent, or Firm* — Sughrue Mion, PLLC

(57) **ABSTRACT**

An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect.

The present invention provides a compound represented by the general formula (I):

(Continued)

